Towards a molecular systems model of coronary artery disease

Current Cardiology Reports

Volumn 16, Issue 6, 2014, Pages

  Abraham, Gad ^a   Bhalala, Oneil G ^a   De Bakker, Paul I W ^b,c   Ripatti, Samuli ^d,e   Inouye, Michael ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Coronary artery disease; Coronary heart disease; Genomics; Mendelian randomization; Metabolites; Molecular systems model; Network analysis; Systems biology

Indexed keywords

CARDIOVASCULAR RISK; CHROMOSOME MAP; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; EXOME; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOME; GENOTYPE; HEART INFARCTION; HERITABILITY; HUMAN; INFLAMMATION; METABOLOMICS; NONHUMAN; PATHOGENESIS; PREDICTION; REVIEW; RISK ASSESSMENT; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS; CHEMICAL STRUCTURE; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MALE; PROTEIN MICROARRAY;

CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MODELS, MOLECULAR; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ARRAY ANALYSIS;

EID: 84901378042     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0488-1     Document Type: Review

References (92)

1. World Health Organization. The top 10 causes of death: fact sheet. 2013.
2. Mackay J, Mensah GA, Mendis S, Greenlund K, World Health Organization. The atlas of heart disease and stroke. Geneva: World Health Organization; 2004. 112 p. p.
3. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004;148:7-15. (Pubitemid 38900475)
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-26. (Pubitemid 29054847)
5. Zdravkovic S, Wienke A, Pedersen NL, Marenberg ME, Yashin AI, et al. Heritability of death from coronary heart disease: a 36-year follow-up of 20,966 Swedish twins. J Intern Med. 2002;252:247-54.
6. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041-6. (Pubitemid 24106561)
7. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921. (Pubitemid 32165345)
8. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. The sequence of the human genome. Science. 2001;291:1304-51. (Pubitemid 32173090)
9. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491-3. (Pubitemid 46906618)
10. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488-91. (Pubitemid 46906617)
11. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature. 2007;447:661-78.
12. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, et al. Genome wide association analysis of coronary artery disease. N Engl J Med. 2007;357:443-53. (Pubitemid 47204873)
13. Roberts R, Stewart AF. Genetics of coronary artery disease in the 21st century. Clin Cardiol. 2012;35:536-40.
14. Shen GQ, Rao S, Martinelli N, Li L, Olivieri O, et al. Association between four SNPs on chromosome 9p21 and myocardial infarction is replicated in an Italian population. J Hum Genet. 2008;53:144-50.
15. Hinohara K, Nakajima T, Takahashi M, Hohda S, Sasaoka T, et al. Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in Japanese and Korean populations. J Hum Genet. 2008;53:357-9.
16. Maitra A, Dash D, John S, Sannappa PR, Das AP, et al. A common variant in chromosome 9p21 associated with coronary artery disease in Asian Indians. J Genet. 2009;88:113-8.
17. Visel A, Zhu Y, May D, Afzal V, Gong E, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010;464:409-12.
18. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signaling response. Nature. 2011;470:264-8.
19. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL expression. PLoS Genet. 2010;6:e1000899.
20. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, et al. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One. 2009;4:e5027.
21. O'Donnell CJ, Kavousi M, Smith AV, Kardia SL, Feitosa MF, et al. Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. Circulation. 2011;124:2855-64.
22. van Setten J, Isgum I, Smolonska J, Ripke S, de Jong PA, et al. Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction. Atherosclerosis. 2013;228:400-5.
23. Shea J, Agarwala V, Philippakis AA, Maguire J, Banks E, et al. Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. Nat Genet. 2011;43:801-5.
24. Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217-24. (Pubitemid 351171400)
25. Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet. 2009;41:283-5.
26. Brazier L, Tiret L, Luc G, Arveiler D, Ruidavets JB, et al. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. Atherosclerosis. 1999;144:323-33. (Pubitemid 29305466)
27. Keenan TE, Rader DJ. Genetics of lipid traits and relationship to coronary artery disease. Curr Cardiol Rep. 2013;15:396.
28. Soranzo N, Spector TD, Mangino M, Kuhnel B, Rendon A, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009;41:1182-90.
29. McPherson R. From genome-wide association studies to functional genomics: new insights into cardiovascular disease. Can J Cardiol. 2013;29:23-9.
30. Schunkert H, Erdmann J, Samani NJ. Genetics of myocardial infarction: a progress report. Eur Heart J. 2010;31:918-25.
31. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747-53.
32. Eichler EE, Flint J, Gibson G, Kong A, Leal SM, et al. Missing heritability and strategies for finding the underlying causes of complex disease. Nat Rev Genet. 2010;11:446-50.
33. Preuss M, Konig IR, Thompson JR, Erdmann J, Absher D, et al. Design of the Coronary ARtery DIsease Genome-Wide Replication and Meta-Analysis (CARDIoGRAM) Study: a genome-wide association meta-analysis involving more than 22,000 cases and 60,000 controls. Circ Cardiovasc Genet. 2010;3:475-83.
34. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333-8.
35. Coronary Artery Disease Genetics C. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011;43:339-44.
36. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45:25-33.
37. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. (Pubitemid 28213628)
38. Ripatti SSV. How could use of genetic markers prevent coronary heart disease events? Personalized Med. 2013;10:769-71.
39. • Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, et al. A multi-locus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393-400. This paper showed that a genetic risk score of 13 loci can capture similar prospective risk for coronary heart disease as classical risk factors like systolic blood pressure, even after adjusting for known Framingham risk factors.
40. Thanassoulis G, Peloso GM, Pencina MJ, Hoffmann U, Fox CS, et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham Heart Study. Circ Cardiovasc Genet. 2012;5:113-21.
41. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, et al. MORGAM (an international pooling of cardiovascular cohorts). Int J Epidemiol. 2005;34:21-7. (Pubitemid 40347364)
42. Hughes MF, Saarela O, Stritzke J, Kee F, Silander K, et al. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One. 2012;7:e40922.
43. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2261-6.
44. van't Hof FN, Ruigrok YM, Baas AF, Kiemeney LA, Vermeulen SH, et al. Impact of inherited genetic variants associated with lipid profile, hypertension, and coronary artery disease on the risk of intracranial and abdominal aortic aneurysms. Circ Cardiovasc Genet. 2013;6:264-70.
45. Abraham G, Kowalczyk A, Zobel J, Inouye M. Performance and robustness of penalized and unpenalized methods for genetic prediction of complex human disease. Genet Epidemiol. 2013;37:184-95.
46. • Inouye M, Ripatti S, Kettunen J, Lyytikäinen L-P, Oksala N, et al. Novel loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. PLoS Genet. 2012;8:e1002907. This paper showed that multivariate genetic association analysis of multiple phenotypes simultaneously (eg, blood metabolites) conferred large gains in statistical power and identified new loci relevant for cardiovascular disease.
47. Alon U. An introduction to systems biology: design principles of biological circuits. Boca Raton: Chapman & Hall/CRC; 2007. xvi, 301 p., 304 p. of plates p.
48. Patino WD, Mian OY, Kang JG, Matoba S, Bartlett LD, et al. Circulating transcriptome reveals markers of atherosclerosis. Proc Natl Acad Sci U S A. 2005;102:3423-8. (Pubitemid 40328061)
49. Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 2007;8:R200.
50. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339:161-6.
51. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, et al. Variations in DNA elucidate molecular networks that cause disease. Nature. 2008;452:429-35. (Pubitemid 351450844)
52. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. 2005;37:710-7. (Pubitemid 41754887)
53. Yang X, Deignan JL, Qi H, Zhu J, Qian S, et al. Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet. 2009;41:415-23.
54. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, et al. Genetics of gene expression and its effect on disease. Nature. 2008;452:423-8. (Pubitemid 351450845)
55. Pearl J. Causality: models, reasoning, and inference. Cambridge, New York: Cambridge University Press; 2000. xvi, 384 p. p.
56. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey SG. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27:1133-63. (Pubitemid 351395448)
57. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomization and causal inference in observational epidemiology. PLoS Med. 2008;5:e177.
58. • Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian Randomization study. Lancet. 2012;380:572-80. This paper is a good example of how Mendelian Randomization can be applied to understand causality in cardiovascular disease. Similar approaches can be utilized at a systems level.
59. Aten JE, Fuller TF, Lusis AJ, Horvath S. Using genetic markers to orient the edges in quantitative trait networks: the NEO software. BMC Syst Biol. 2008;2:34.
60. Logsdon BA, Mezey J. Gene expression network reconstruction by convex feature selection when incorporating genetic perturbations. PLoS Comput Biol. 2010;6:e1001014.
61. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38:1092-104.
62. Laurila PP, Surakka I, Sarin AP, Yetukuri L, Hyotylainen T, et al. Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol. 2013;33:847-57.
63. • Huan T, Zhang B, Wang Z, Joehanes R, Zhu J, et al. A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:1427-34. This paper utilized sophisticated multi-scale network analyses to identify tissue localized gene effects proposed to be causal of coronary heart disease.
64. Suhre K, Gieger C. Genetic variation in metabolic phenotypes: study designs and applications. Nat Rev Genet. 2012;13:759-69.
65. Suhre K, Shin S-Y, Petersen A-K, Mohney RP, Meredith D, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477:54-60.
66. Hansson GK, Jonasson L. The discovery of cellular immunity in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2009;29:1714-7.
67. Insull Jr W. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122:S3-14.
68. Kettunen J, Tukiainen T, Sarin A-P, Ortega-Alonso A, Tikkanen E, et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet. 2012;44:269-76.
69. Inouye M, Silander K, Hamalainen E, Salomaa V, Harald K, et al. An immune response network associated with blood lipid levels. PLoS Genet. 2010;6:e1001113.
70. Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, et al. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol. 2010;6:441.
71. Caesar R, Fak F, Backhed F. Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism. J Intern Med. 2010;268:320-8.
72. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480-4.
73. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541-6.
74. Gaetti-Jardim Jr E, Marcelino SL, Feitosa AC, Romito GA, Avila-Campos MJ. Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. J Med Microbiol. 2009;58:1568-75.
75. Koren O, Spor A, Felin J, Fak F, Stombaugh J, et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4592-8.
76. Parks BW, Nam E, Org E, Kostem E, Norheim F, et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab. 2013;17:141-52.
77. Ordovas JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev Cardiol. 2010;7:510-9.
78. Gluckman PD, Hanson MA, Buklijas T, Low FM, Beedle AS. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat Rev Endocrinol. 2009;5:401-8.
79. Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, et al. Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Science. 2013;339:448-52.
80. Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, et al. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer. 2009;115:3412-26.
81. Yideng J, Jianzhong Z, Ying H, Juan S, Jinge Z, et al. Homocysteine-mediated expression of SAHH, DNMTs, MBD2, and DNA hypomethylation potential pathogenic mechanism in VSMCs. DNA Cell Biol. 2007;26:603-11. (Pubitemid 47263207)
82. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570-3.
83. Yeung KY, Dombek KM, Lo K, Mittler JE, Zhu J, et al. Construction of regulatory networks using expression time-series data of a genotyped population. Proc Natl Acad Sci U S A. 2011;108:19436-41.
84. Lebre S, Becq J, Devaux F, Stumpf MP, Lelandais G. Statistical inference of the time-varying structure of gene-regulation networks. BMC Syst Biol. 2010;4:130.
85. Chen R, Mias GI, Li-Pook-Than J, Jiang L, Lam HY, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148:1293-307.
86. Nica AC, Parts L, Glass D, Nisbet J, Barrett A, et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet. 2011;7:e1002003.
87. Dimas AS, Deutsch S, Stranger BE, Montgomery SB, Borel C, et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science. 2009;325:1246-50.
88. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580-5.
89. Roden DM, Johnson JA, Kimmel SE, Krauss RM, Medina MW, et al. Cardiovascular pharmacogenomics. Circ Res. 2011;109:807-20.
90. Weeke P, Roden DM. Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep. 2013;15:376.
91. Ioannidis JP. To replicate or not to replicate: the case of pharmacogenetic studies: have pharmacogenomics failed, or do they just need larger-scale evidence and more replication? Circ Cardiovasc Genet. 2013;6:413-8. discussion 418.
92. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94:317-23.